Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next predicted deadline: Oct 5, 2023

Later predicted deadlines: Feb 5, 2024, Jun 5, 2024, Oct 5, 2024, Feb 5, 2025

Grant amount: Unspecified amount

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization. 

This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. 

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.